Pulnovo Medical Secures $100 Million Investment from Medtronic for Pulmonary Hypertension Therapies

Key Takeaways

• Pulnovo Medical completed an oversubscribed $100 million financing round with strategic investment from medical device giant Medtronic
• The funding will accelerate development of breakthrough therapies for pulmonary hypertension and heart failure patients
• Existing investors including EQT, Qiming Venture Partners, and OrbiMed continued their support in the strategic round

---

NEW YORK, April 19, 2026 — Pulnovo Medical, a pioneer in breakthrough therapies for treating pulmonary hypertension and heart failure, announced the successful completion of an oversubscribed $100 million strategic financing round led by Medtronic, one of the world’s largest medical technology companies.

Strategic Partnership with Medical Device Leader

The investment represents a significant vote of confidence in Pulnovo’s innovative approach to cardiovascular therapeutics. Medtronic’s participation as the lead investor brings not only substantial capital but also potential synergies in medical device development and global market access.

Existing investors demonstrated continued confidence by participating in the round, including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures. This diverse investor base spans venture capital, private equity, and pharmaceutical industry players.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Addressing Critical Cardiovascular Conditions

Pulmonary hypertension affects an estimated 15-50 people per million globally and can lead to right heart failure if left untreated. Current treatment options remain limited, creating significant unmet medical need for innovative therapeutic approaches.

The cardiovascular medical device market is projected to reach $79.4 billion by 2030, driven by aging populations and increasing prevalence of heart conditions. Pulnovo’s positioning in this growing market, combined with Medtronic’s expertise in cardiovascular devices, could accelerate development timelines.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Future Outlook

The oversubscribed nature of the financing round indicates strong investor appetite for cardiovascular innovation. For Medtronic, the investment aligns with its strategy to expand its cardiovascular portfolio through strategic partnerships with emerging companies developing breakthrough technologies.

The funding will likely support clinical trials, regulatory submissions, and manufacturing scale-up for Pulnovo’s therapeutic candidates. With Medtronic’s global reach and regulatory expertise, Pulnovo may be positioned to accelerate international expansion once products receive regulatory approval.

---

Frequently Asked Questions

What does this investment mean for pulmonary hypertension patients?

The $100 million funding will accelerate development of Pulnovo’s breakthrough therapies, potentially bringing new treatment options to market faster for patients with limited current therapeutic choices.

When will Pulnovo’s treatments be available to patients?

While specific timelines weren’t disclosed, the substantial funding will support clinical trials and regulatory submissions, though availability depends on successful trial outcomes and regulatory approvals.

How does Medtronic’s investment benefit Pulnovo’s development?

Beyond capital, Medtronic brings medical device expertise, global market access, regulatory knowledge, and potential manufacturing capabilities that could accelerate Pulnovo’s path to market.